New Nordic Healthbrands AB (NNH) Fair Value & Analysis
Consumer Defensive · SE · Market cap 87.4M SEK
Fair value as of: Jun 25, 2026
Analysis
New Nordic Healthbrands AB (NNH) currently trades at kr 12.80, while our model-based Fair Value estimate is kr 26.34 — implying the stock looks roughly 105.8% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
New Nordic Healthbrands AB (publ) manufactures and sells dietary supplements, herbal remedies, and related personal care products in the Nordic countries, rest of Europe, North America, and internationally. The company offers body care, dietary supplements, facial care, assortment, and natural magic trio products; hair volume series, dietary supplements, shampoo and conditioner, hair care, and range products; vitality products, such as vitamins and minerals, body, fish oil and omega-3, menopause, sleep and relaxation, men's health, and magnesium products; detox, digestion, and weight loss products. It sells its products under the NEW NORDIC brand through pharmacies, department stores, travel retailers, health stores, e-commerce, and direct to consumers. New Nordic Healthbrands AB (publ) was founded in 1990 and is headquartered in Malmö, Sweden.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is New Nordic Healthbrands AB (NNH) undervalued?
What is the fair value of NNH?
What is the quality score of NNH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.